| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 1999;30:427-432.)
© 1999 American Heart Association, Inc.
Original Contributions |
Synergistic Effects of a Combination of Low-Dose Basic Fibroblast Growth Factor and Citicoline After Temporary Experimental Focal Ischemia
From the Department of Neurology, Memorial Health Care (W.R.S., F.L., K.I., M.F.), Department of Neurology, The University of Massachusetts Medical School (M.F.), Worcester, Mass, and Interneuron Pharmaceuticals, Inc (B.W.S., K.W.L.), Lexington, Mass.
Background and Purpose—Basic fibroblast growth factor (bFGF) and citicoline (cytidine 5'-diphosphate choline, an endogenous compound that stabilizes membrane function) have demonstrated neuroprotective effects after focal cerebral ischemia. Both agents are candidates for future stroke therapy in humans. For evaluation of synergistic effects of bFGF and citicoline, a low-dose combination of both compounds was tested against each compound alone and placebo.
Methods—Four groups of Sprague-Dawley rats (n=12 per group) underwent 90 minutes of focal cerebral ischemia with the use of the suture model of middle cerebral artery occlusion. Animals were randomly and blindly assigned to one of the following treatment groups: placebo, low-dose citicoline (250 mg/kg IP daily for 4 days), low-dose bFGF (10 µg/kg per hour IV for 3 hours), and the combination of both (250 mg/kg citicoline and 10 µg/kg per hour bFGF). Triphenyltetrazolium chloride staining was used after 4 days to determine postmortem infarction. Neurological scores were assessed on a daily basis.
Results—The premature mortality rate was 41.7% in the placebo and citicoline groups, 33.3% in the bFGF group, and 25% (P=NS) in the combination group. The mean neurological score on day 4 was 3.1±1.6 (placebo), 3.1±1.6 (citicoline), 2.9±1.5 (bFGF), and 2.4±1.4 (combination) (P=NS). The mean volume of infarction was significantly reduced in the combination group (136.5±25.4 mm3) versus placebo (172.6±48.9 mm3; P=0.036, Fisher test), versus citicoline alone (186.0±35.7 mm3; P=0.005, Fisher test), and versus bFGF alone (176.0±49.2 mm3; P=0.023, Fisher test).
Conclusions—These results demonstrate synergistic effects of a low-dose combination of the growth factor bFGF and citicoline after temporary experimental focal cerebral ischemia and furthermore support the effectiveness of a combination treatment regimen for the management of acute stroke.
Editorial Comment
Anesthesiology/Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland
This article has been cited by other articles:
 |
|
 |
|
  C. Grommes, G. E. Landreth, M. Sastre, M. Beck, D. L. Feinstein, A. H. Jacobs, U. Schlegel, and M. T. Heneka Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor {gamma} Agonist Treatment Mol. Pharmacol., November 1, 2006; 70(5): 1524 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher, A. Davalos, A. Rogalewski, A. Schneider, E. B. Ringelstein, and W.-R. Schabitz Toward a Multimodal Neuroprotective Treatment of Stroke Stroke, April 1, 2006; 37(4): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Adibhatla, J. F. Hatcher, E. C. Larsen, X. Chen, D. Sun, and F. H. C. Tsao CDP-choline Significantly Restores Phosphatidylcholine Levels by Differentially Affecting Phospholipase A2 and CTP: Phosphocholine Cytidylyltransferase after Stroke J. Biol. Chem., March 10, 2006; 281(10): 6718 - 6725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meisel, K. Prass, J. Braun, I. Victorov, T. Wolf, D. Megow, E. Halle, H.-D. Volk, U. Dirnagl, and A. Meisel Preventive Antibacterial Treatment Improves the General Medical and Neurological Outcome in a Mouse Model of Stroke Stroke, January 1, 2004; 35(1): 2 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Prass, C. Meisel, C. Hoflich, J. Braun, E. Halle, T. Wolf, K. Ruscher, I. V. Victorov, J. Priller, U. Dirnagl, et al. Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Poststroke T Helper Cell Type 1-like Immunostimulation J. Exp. Med., September 2, 2003; 198(5): 725 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-R. Schabitz, T. T. Hoffmann, S. Heiland, R. Kollmar, J. Bardutzky, C. Sommer, and S. Schwab Delayed Neuroprotective Effect of Insulin-Like Growth Factor-I After Experimental Transient Focal Cerebral Ischemia Monitored With MRI Stroke, May 1, 2001; 32(5): 1226 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Traystman, J. A. Klaus, A. C. DeVries, A. B. Shaivitz, and P. D. Hurn Anticonvulsant Lamotrigine Administered on Reperfusion Fails To Improve Experimental Stroke Outcomes Stroke, March 1, 2001; 32(3): 783 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and W. Schaebitz An Overview of Acute Stroke Therapy: Past, Present, and Future Arch Intern Med, November 27, 2000; 160(21): 3196 - 3206. [Full Text] [PDF]
|
|
|
|
|
|
T. Omae, O. Mayzel-Oreg, F. Li, C. H. Sotak, M. Fisher, and E. C. Haley Jr Inapparent Hemodynamic Insufficiency Exacerbates Ischemic Damage in a Rat Microembolic Stroke Model Editorial Comment Stroke, October 1, 2000; 31(10): 2494 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-R. Schabitz, C. Sommer, W. Zoder, M. Kiessling, M. Schwaninger, S. Schwab, and S. P. Finklestein Intravenous Brain-Derived Neurotrophic Factor Reduces Infarct Size and Counterregulates Bax and Bcl-2 Expression After Temporary Focal Cerebral Ischemia Editorial Comment Stroke, September 1, 2000; 31(9): 2212 - 2217. [Abstract] [Full Text] [PDF]
|
|